Targeting BRAF-mutant tumours with TGFBR1 inhibitors

Aging (Albany NY). 2017 Jan 31;9(1):5-6. doi: 10.18632/aging.101169.

Authors

Lindsay C Spender¹, Gareth J Inman¹

Affiliation

¹ Division of Cancer Research, School of Medicine, University of Dundee, Dundee, UK.

No abstract available

Keywords: BRAF; TGFβ; melanoma; therapy.

Publication types

Editorial

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Humans
Mutation
Neoplasms / drug therapy*
Neoplasms / genetics*
Protein Kinase Inhibitors / pharmacology*
Protein Serine-Threonine Kinases / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics*
Receptor, Transforming Growth Factor-beta Type I
Receptors, Transforming Growth Factor beta / antagonists & inhibitors*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Receptors, Transforming Growth Factor beta
BRAF protein, human
Protein Serine-Threonine Kinases
Proto-Oncogene Proteins B-raf
Receptor, Transforming Growth Factor-beta Type I
TGFBR1 protein, human